Zürich University Hospital has started using Stockholm3 for prostate cancer testing. This is the first clinic in Switzerland that uses Stockholm3.
Stockholm3 will be used for men aged 45 to 75 and offered to men in Switzerland. The blood tests will be taken at the Zürich University Hospital and the test analysis will be performed by A3P at its laboratory facility in Uppsala, Sweden. Men that have an elevated risk for prostate cancer will be offered an MRI examination and state-of-the-art prostate biopsy for further medical clarification. The University Hospital Zürich provides a great bandwidth of interdisciplinary treatment options ranging from focal therapy to surgery and medical and radiotherapy.
“Early detection of prostate cancer is of utmost importance for therapy success and quality of life of the patient. Thus, prostate cancer screening has to be elevated to the next level of innovation and precision. We are therefore very happy that we can now offer Stockholm3 to our patients to improve treatment and well-being,” says Professor Dr Daniel Eberli, clinic director for the urology clinic of Zürich University Hospital.
“We see a growing interest for Stockholm3 from clinicians all over the world and are very happy that the test is now available for Swiss men for the first time,” says David Rosén, CEO of A3P Biomedical.
Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100% more aggressive prostate cancers and reduces 50% of unnecessary biopsies compared to current practice with PSA (prostate-specific antigen).
Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomised study including 12,750 men, was published in The Lancet Oncology in 2021. The study was also awarded the European Association of Urology (EAU) ‘Prostate Cancer Research Award 2022’. Multiple additional studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015.
Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio Saint Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. The Region Värmland area has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 – 28%.
